RecruitingNCT03349762

Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery

A Real-World Study Investigating Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery

Sponsor

Xi Shan Wang

Enrollment

3,060 participants

Start Date

Nov 2, 2018

Study Type

OBSERVATIONAL

Conditions

Colorectal, Cancer

Summary

To evaluate the efficacy and safety of Huaier granules for Prevention of Recurrence and Metastasis of colorectal cancer patients following radical surgery

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether a traditional Chinese herbal medicine called Huaier Granules, taken after surgery for colorectal cancer (bowel cancer), can help prevent the cancer from coming back or spreading to other parts of the body. **You may be eligible if...** - You are between 18 and 75 years old (male or female) - You had surgery to remove colorectal cancer within the last two months - Your cancer was confirmed by pathology as stage IIB, IIC, or III (cancer that has spread to nearby lymph nodes but not distant organs) - You are in reasonably good overall health (ECOG score of 0 to 2) - You have no previous history of other cancers - You are willing to participate and sign an informed consent form **You may NOT be eligible if...** - You have had previous cancer treatments before surgery - You have other serious health conditions that could interfere with the study - You have a history of other cancers Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(22)

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

The First Clinical Hospital affiliated to Harbin Medical University

Harbin, Heilongjiang, China

The Second Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Hubei Cancer Hospita

Wuhan, Hubei, China

Union Hospital Tongji College Huazhong University of Science and Technology

Wuhan, Hubei, China

Hunan Provincial People's Hospital

Changsha, Hunan, China

Xiangya Hospital Central South University

Changsha, Hunan, China

Changzhou No.2 People's Hospital

Changzhou, Jiangsu, China

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China

Northern Jiangsu People's Hospital

Yangzhou, Jiangsu, China

Anshan Cancer Hospital

Anshan, Liaoning, China

Ansteel Group General Hospital

Anshan, Liaoning, China

The First Affiliated Hospital of Jinzhou Medical University

Jinzhou, Liaoning, China

Shandong Provincial Hospital

Jinan, Shandong, China

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Yantai Yuhuangding Hospital

Yantai, Shandong, China

Zaozhuang Municipal Hospital

Zaozhuang, Shandong, China

First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China

Fudan University Shanghai Cancer Center

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03349762

Related Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

NCT0600424529 locations

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

NCT067280722 locations

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT073001505 locations

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT073188059 locations

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

NCT062058361 location